GlobalData analyzed the BPH therapeutic pipeline and found it to be strong. The pipeline for BPH therapeutics consists of approximately 21 molecules in different stages of development. More than 80% of the BPH therapeutics pipeline is captured by first-in-class molecules. Most of these molecules hold promise, with a novel mechanism of action and good efficacy and safety profiles. The BPH therapeutics pipeline does not have any me-too molecules. Eli Lilly’s Cialis is one of the most promising molecules that been filed with the US FDA (Food and Drug Administration) for marketing approval to treat BPH. Nymox’s NX-1207 is a novel injectable therapy and is expected to be launched in the US and the EU by 2014, which will drive the saturated BPH therapeutics market.
Hey, just realize things are much closer than you guys know and to verify it just call Dr Paul. What he can say is nothing because he is still not allowed to speak. In the past he shouted from the roof tops and had no problems talking to most share holders. This is actually a great sign for those long.